These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14703957)

  • 1. Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus.
    Czock D; Aisenpreis U; Rasche FM; Jehle PM
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):492-7. PubMed ID: 14703957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin lispro: its role in the treatment of diabetes mellitus.
    Campbell RK; Campbell LK; White JR
    Ann Pharmacother; 1996 Nov; 30(11):1263-71. PubMed ID: 8913409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures.
    Roach P; Woodworth JR
    Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.
    ter Braak EW; Woodworth JR; Bianchi R; Cerimele B; Erkelens DW; Thijssen JH; Kurtz D
    Diabetes Care; 1996 Dec; 19(12):1437-40. PubMed ID: 8941480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
    Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A; Jacobsen LV
    Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients.
    Rave K; Heise T; Pfützner A; Heinemann L; Sawicki PT
    Diabetes Care; 2001 May; 24(5):886-90. PubMed ID: 11347749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
    Wilde MI; McTavish D
    Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase.
    Hompesch M; Muchmore DB; Morrow L; Ludington E; Vaughn DE
    Diabetes Technol Ther; 2012 Mar; 14(3):218-24. PubMed ID: 22136324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.
    Anderson JH; Brunelle RL; Koivisto VA; Trautmann ME; Vignati L; DiMarchi R
    Clin Ther; 1997; 19(1):62-72. PubMed ID: 9083709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus.
    Aisenpreis U; Pfützner A; Giehl M; Keller F; Jehle PM
    Nephrol Dial Transplant; 1999; 14 Suppl 4():5-6. PubMed ID: 10463187
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin glulisine: a faster onset of action compared with insulin lispro.
    Heise T; Nosek L; Spitzer H; Heinemann L; Niemöller E; Frick AD; Becker RH
    Diabetes Obes Metab; 2007 Sep; 9(5):746-53. PubMed ID: 17593235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin lispro: a review of its use in the management of diabetes mellitus.
    Simpson D; McCormack PL; Keating GM; Lyseng-Williamson KA
    Drugs; 2007; 67(3):407-34. PubMed ID: 17335298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.